Translating Cardioprotection for Patient Benefit: The EU-CARDIOPROTECTION COST Action

J Am Coll Cardiol. 2019 Apr 23;73(15):2001-2003. doi: 10.1016/j.jacc.2019.03.020.

Authors

Derek J Hausenloy¹, Gerd Heusch²

Affiliations

¹ The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, United Kingdom; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore.
² Institute for Pathophysiology, West German Heart and Vascular Centre, University of Essen Medical School, Essen, Germany. Electronic address: Gerd.Heusch@uk-essen.de.

PMID: 31000004
DOI: 10.1016/j.jacc.2019.03.020

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Cardiotonic Agents / administration & dosage*
European Union
Health Workforce / organization & administration*
Heart Failure / etiology
Heart Failure / prevention & control*
Humans
Myocardial Infarction / complications*
Myocardial Infarction / diagnosis
Myocardial Infarction / therapy
Patient Safety*
Research Design
Risk Assessment

Substances

Cardiotonic Agents

Grants and funding